海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cells
- mRNA FGF receptor 1 and 3 positive locally advanced or metastatic urothelial carcinoma progressed after prior platinum-containing chemotherapy MedDRA version: 20.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Democratic People's Republic of, Netherlands, Poland, Portugal, Russian Federation, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
- 2018-01-18
Authorised
- A pilot study to assess the impact of genetic polymorphisms in the ABCB1 and ABCG2 genes on brain and organ penetration of dual Pgp/BCRP substrates in humans.
- The effect of genetic polymorphisms on drug distribution will be investigated in healthy volunteers;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
- Austria
- 2014-03-19
Authorised
- Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer.
- Unresectable Wild-Type KRAS Metastatic Colorectal Cancer MedDRA version: 16.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, France, Ireland, Israel, Italy, Spain
- 2013-05-22
Authorised
- First-line treatment for different subgroups of lymphomas
- Indolent Non-Hodgkin Lymphomas, in particular follicular lymphomas, as well as marginal zone lymphomas, immunocytomas (Waldenström’s macroglobulinaemia) and mantle cell lymphomas;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Germany
- 2008-11-20
Authorised
- Pembrolizumab as First Line Treatment in Subjects with Recurrent/Metastatic HNSCC.
- Recurrent/metastatic head and neck squamous cell carcinoma. MedDRA version: 20.0 Level: PT Classification code 10071540 Term: Head and neck cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Latvia, Malaysia, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States
- 2014-12-22
Authorised
- Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line treatment for R/M HNSCC (KEYNOTE-669/ECHO-304)
- Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Brazil, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Spain, Taiwan, Turkey, United Kingdom, United States
- 2017-10-24
Authorised
- Pembrolizumab (MK-3475) as First-Line Therapy for Advanced Merkel Cell Carcinoma
- Unresectable Stage III and Stage IV Merkel Cell Carcinoma (MCC) MedDRA version: 20.0 Level: LLT Classification code 10064025 Term: Merkel cell carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, France, Italy, New Zealand, Spain, Sweden, United States
- 2018-10-24
Authorised
- First-line chemotherapy plus pembrolizumab and olaparib for BRCA non-mutated advanced EOC
- Advanced epithelial ovarian cancer MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2018-10-23
Authorised
- A Phase 1/2 study to test how effective different doses of MEDI-551 is for treating subjects with Relapsing-Remitting Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Austria, Canada, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2012-03-05
Authorised
- Feasibility study to test an insulin dosing algorithm in type 1 diabetic patients
- Diabetes mellitus type 1;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
- Austria
- 2013-01-10